{"id":47359,"date":"2020-11-13T22:59:09","date_gmt":"2020-11-13T14:59:09","guid":{"rendered":"https:\/\/www.chinapulse.com\/?p=133137"},"modified":"2020-11-13T22:59:09","modified_gmt":"2020-11-13T14:59:09","slug":"shanghai-junshi-delays-drug-trials-focuses-on-covid-19-treatment","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2020\/11\/13\/shanghai-junshi-delays-drug-trials-focuses-on-covid-19-treatment\/","title":{"rendered":"Shanghai Junshi delays drug trials, focuses on COVID-19 treatment"},"content":{"rendered":"<p>BEIJING (Reuters) &#8211; A shortage of lab monkeys and a focus on developing a COVID-19 treatment have prompted Shanghai Junshi Biosciences to push back clinical trials of some other drugs, an executive at U.S. drugmaker Eli Lilly&#8217;s Chinese partner said.<\/p>\n<p>Junshi&#8217;s   experimental COVID-19 antibody treatment, JS016, is in early to mid-stage trials in the United States and Eli Lilly plans to combine it with another candidate and apply for a U.S.&#8230;<\/p>\n<p>This news comes via <a href=\"https:\/\/www.chinapulse.com\/\"  title=\"Best source for Chinese news in English\">ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING (Reuters) &#8211; A shortage of lab monkeys and a focus on developing a COVID-19 treatment have prompted Shanghai Junshi Biosciences to push back clinical trials of some other drugs, an executive at U.S. drugmaker Eli Lilly's Chinese part&#8230;<\/p>\n","protected":false},"author":250,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65,213,288,194,494,401,484,296],"tags":[3472,10323,10324,10328],"class_list":["post-47359","post","type-post","status-publish","format-standard","hentry","category-beijing","category-china-news","category-medicine","category-news-chinese-law","category-pharmaceutical","category-shanghai","category-united-states","category-world-health-organization","tag-chinese","tag-coronavirus","tag-covid-19","tag-pandemic"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/47359"}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/250"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=47359"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/47359\/revisions"}],"predecessor-version":[{"id":47360,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/47359\/revisions\/47360"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=47359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=47359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=47359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}